Jeffrey J. Hessekiel, insider at Exelixis

Jeffrey J. Hessekiel Insider Information

EVP of Exelixis
Jeffrey J. Hessekiel, J.D., has served as Executive Vice President and General Counsel since February 2014 and as its Secretary from October 2014 to September 2017. From 2012 to 2014, he held the position of Senior Counsel at Arnold & Porter Kaye Scholer LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Prior to working with Arnold & Porter, from 2002 to 2012, he held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Chief Compliance & Quality Officer where he was responsible for the creation and management of Gilead’s Corporate Compliance & Quality department. From 1998 to 2002, Mr. Hessekiel held the position of Associate, working on both litigation and corporate matters for Wilson Sonsini Goodrich and Rosati PC. Mr. Hessekiel also worked as an Associate focusing on litigation matters for Heller Ehrman LLP from 1996 to 1998. Prior to joining Heller Ehrman LLP, Mr. Hessekiel also worked for several international non-governmental organizations. Mr. Hessekiel received his J.D. from The George Washington University Law School and is admitted to practice in California. Mr. Hessekiel received a B.A. in Political Science from Duke University.

How old is Jeffrey J. Hessekiel?

Mr. Hessekiel is currently 53 years old. There are 5 older executives and no younger executives at Exelixis. The oldest executive at Exelixis is Dr. Stelios Papadopoulos Ph.D., Co-Founder & Independent Chair of the Board, who is 74 years old. Learn More on Jeffrey J. Hessekiel's age.

What is Jeffrey J. Hessekiel's salary?

As the EVP of Exelixis, Inc., Mr. Hessekiel earned a total compensation package of $2,147,751.00 in 2021. Mr. Hessekiel earned a salary of $599,135.00, stock awards of $1,217,547.00, non-equity compensation of $347,069.00, and other compensation of $11,000.00. Learn More on Jeffrey J. Hessekiel's salary.

How do I contact Jeffrey J. Hessekiel?

The corporate mailing address for Mr. Hessekiel and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected] Learn More on Jeffrey J. Hessekiel's contact information.

Has Jeffrey J. Hessekiel been buying or selling shares of Exelixis?

Jeffrey J. Hessekiel has not been actively trading shares of Exelixis within the last three months. Most recently, Jeffrey Hessekiel sold 4,717 shares of the business's stock in a transaction on Monday, March 28th. The shares were sold at an average price of $22.00, for a transaction totalling $103,774.00. Learn More on Jeffrey J. Hessekiel's trading history.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Charles Cohen (Director), Carl Feldbaum (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.

Are insiders buying or selling shares of Exelixis?

In the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 473,894 shares worth more than $9,146,006.43. The most recent insider tranaction occured on May, 27th when EVP Patrick J Haley sold 18,812 shares worth more than $342,566.52. Insiders at Exelixis own 2.9 % of the company. Learn More about insider trades at Exelixis.

Information on this page was last updated on 5/27/2022.

Jeffrey J. Hessekiel Insider Trading History at Exelixis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2022Sell4,717$22.00$103,774.00View SEC Filing Icon  
2/24/2022Sell18,000$20.00$360,000.00View SEC Filing Icon  
11/1/2021Sell5,117$22.03$112,727.51View SEC Filing Icon  
10/21/2020Sell39,742$21.95$872,336.90View SEC Filing Icon  
5/11/2020Sell38,006$27.09$1,029,582.54View SEC Filing Icon  
8/16/2019Sell75,000$21.10$1,582,500.00View SEC Filing Icon  
4/1/2019Sell20,000$24.03$480,600.00View SEC Filing Icon  
11/30/2018Sell14,818$19.25$285,246.50View SEC Filing Icon  
11/28/2018Sell11,759$19.12$224,832.08View SEC Filing Icon  
5/31/2018Sell65,000$20.71$1,346,150.00View SEC Filing Icon  
5/4/2018Sell20,000$22.36$447,200.00View SEC Filing Icon  
9/28/2017Sell27,302$24.28$662,892.56View SEC Filing Icon  
3/27/2017Sell6,884$21.02$144,701.68View SEC Filing Icon  
3/22/2017Sell23,787$20.54$488,584.98View SEC Filing Icon  
See Full Table

Jeffrey J. Hessekiel Buying and Selling Activity at Exelixis

This chart shows Jeffrey Hessekiel's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exelixis Company Overview

Exelixis logo
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $19.51
Low: $19.29
High: $19.67

50 Day Range

MA: $20.56
Low: $17.57
High: $22.27

2 Week Range

Now: $19.51
Low: $15.50
High: $23.40


1,225,337 shs

Average Volume

2,269,445 shs

Market Capitalization

$6.28 billion

P/E Ratio


Dividend Yield